

Interim report January 1–September 30, 2022

July–September 2022

- » Net revenue for the period was SEK 237.0 million (105.6), an increase of 124.5 %. Organic growth was 27.2 %.
- » Orders received for the period was SEK 268.4 million (107.1), an increase of 150.7 %. Organic growth was 20.6 %.
- » Adjusted EBITDA for the period was SEK 36.0 million (14.5)
- » EBITDA for the period was SEK 39.2 million (13.3)
- » Profit/loss for the period was SEK 33.9 million (-1.6)
- » Earnings per share for the period amounted to SEK 0.19 (-0.01)
- » Cash flow from Operations for the period was SEK 20.8 million

January–September 2022

- » Net revenue for the period was SEK 631.3 million (310.9), an increase of 103.0 %. Organic growth was 11.4 %.
- » Orders received for the period was SEK 660.1 million (327.4), an increase of 101.6 %. Organic growth was 10.6 %.
- » Adjusted EBITDA for the period was SEK 89.0 million (38.0)
- » EBITDA for the period was SEK 94.7 million (37.9)
- » Profit/loss for the period was SEK 53.0 million (1.0)
- » Earnings per share for the period amounted to SEK 0.30 (0.01)
- » Cash flow from Operations for the period was SEK 42.9 million

SEK THOUSANDS	2022 Jul–Sep	2021 Jul–Sep	2022 Jan–Sep	2021 Jan–Sep	Rolling 12 months Oct 2021– Sep 2022	2021 Jan–Dec	Change	Pro forma rolling 12 months Oct 2021– Sep 2022
Net revenue	236,960	105,557	631,260	310,939	786,274	465,953	68.7%	959,983
EBITDA	39,177	13,272	94,708	37,902	114,068	57,261	99.2%	154,576
EBITDA margin, %	16.5%	12.6%	15.0%	12.2%	14.5%	12.3%	2.2 pp	16.1%
Adjusted EBITDA	35,991	14,510	89,050	38,026	108,082	57,058	89.4%	148,591
Adjusted EBITDA margin, %	15.2%	13.7%	14.1%	12.2%	13.7%	12.2%	1.5 pp	15.5%
EBITA	34,424	10,497	82,107	30,742	98,162	46,797	109.8%	136,688
EBITA margin, %	14.5%	9.9%	13.0%	9.9%	12.5%	10.0%	2.5 pp	14.2%
Profit/loss before tax (EBT)	42,591	-661	63,124	3,566	67,217	7,658	777.7%	105,543
Profit/loss for the period	33,901	-1,564	53,021	1,027	54,799	2,805	1 853.6%	91,625
Adjusted profit/loss for the period	31,437	3,025	58,008	8,947	61,799	12,739	385.1%	98,625
Earnings per share (SEK)	0.19	-0.01	0.30	0.01	0.31	0.02		0.51
Net debt-to-EBITDA	3.8	3.4	3.8	3.4	3.8	4.0		2.8

CEO's comments

A strong quarter of robust organic growth and improved margins

Q3 was characterized by strong organic growth and improved margins. Organic net revenue growth amounted to 27.2 %. This growth was primarily driven by increased demand from our customers, a reduction in supply chain disruptions, and a favorable currency trend. Orders received remained strong, increasing organically by 20.6 % during the quarter.

Adjusted EBITDA improved compared with Q3 2021, amounting to SEK 36.0 million (14.5). We have systematically worked on improving our margins and, despite a challenging environment characterized by inflation and price increases, we have been able to strengthen our EBITDA margin by passing on increased costs to our customers. Currency tailwinds and acquisitions have also contributed to the stronger margins. The Group's adjusted EBITDA margin increased to 15.2 % (13.7) during the quarter.

Our underlying markets are continuing to show strength. Activity in our Healthcare business unit remains high, and the equipment used in day-to-day care see high consumption, especially in the U.S. market, which now accounts for more than 50 % of our business and revenue. With regard to hospital equipment that requires investment decisions, we may see a certain amount of caution at the moment. However, capital goods for hospitals in the United States actually represent less than 5 % of the Group's total revenue.

Investment in research facilities and related equipment remains at a good level. Many projects that did slow down during the pandemic are now being completed, and this is also driving the sale of instruments and consumables used in research. We are seeing a sharp increase in clean room projects in the Middle East as these investments are often linked to the USD and the oil price. We are currently completing a large clean room project in Egypt that will be used in the production of mRNA vaccines.

The Group's order book is now at historically high levels. This situation, combined with healthy organic growth in orders received, means that we have good visibility with the expectation of further strong quarters.



We are continuing to work actively to identify complementary acquisitions. The selection of companies that fit into one of our two business units is good at present. Yet we can also see that there was a slight multiple contraction in private M&A deals during Q3, not least in Sweden. Our priority growth markets are the Nordic region, the United States, and the United Kingdom. These are markets with a strong focus on high-quality research and healthcare, and which also have different but well-functioning healthcare systems. The Group's net interest-bearing liabilities are now below our long-term target of 3.0 times pro forma EBITDA. At the end of Q3 it was 2.8 times pro forma EBITDA. This means that our ability to continue making complementary acquisitions remains.

Rikard Akhtarzand,
CEO, ADDvise Group AB (publ)

The Group's development

Net revenue and orders

Net revenue for the quarter was SEK 237.0 million (105.6), an increase of 124.5 % compared with the same period of the previous year. Organic growth was 27.2 %, without currency rate effects 14.8 %.

Net revenue for January–September was SEK 631.3 million (310.9), an increase of 103.0 % compared with the same period of the previous year. Organic growth was 11.4 %, without currency rate effects 4.7 %.

Orders received for the quarter was SEK 268.4 million (107.1), an increase of 150.7 % compared with the same period of the previous year. Organic growth was 20.6 %.

Orders received for January–September totaled SEK 660.1 million (327.4), an increase of 101.6 % compared with the same period of the previous year. Organic growth was 10.6 %.

Profit

EBITDA for the quarter was SEK 39.2 million (13.3).

Adjusted EBITDA was SEK 36.0 million (14.5). Acquisition costs had a negative impact on EBITDA of SEK 0.6 million (1.6) and restructuring costs had a negative impact of SEK 1.9 million (0.0). EBITDA was positively impacted by state subsidies and similar items related to Covid-19 by SEK 0.1 million (0.3) and revaluation of contingent earn-outs for completed acquisitions of SEK 5.6 million (0.0).

EBITDA for January–September was SEK 94.7 million (37.9). Adjusted EBITDA was SEK 89.0 million (38.0). Acquisition costs had a negative impact on EBITDA of SEK 1.8 million (2.2) and restructuring costs had a negative impact of SEK 1.9 million (0.0). EBITDA was positively impacted by state subsidies and similar items related to Covid-19 by SEK 3.8 million (2.1) and revaluation of contingent earn-outs for completed acquisitions of





SEK 5.6 million (0.0).

EBITA for the quarter was SEK 34.4 million (10.5).

Operating profit/loss for the period was SEK 32.8 million (9.6). Profit/loss after tax was SEK 33.9 million (-1.6).

Adjusted profit/loss after tax amounted to SEK 31.4 million (3.0). Acquisition costs had a negative impact on profit/loss after tax of SEK 1.4 million (4.9), with SEK 0.6 million (1.6) reported in the item Other external expenses and SEK 0.7 million (3.3) reported in the item Net financial items. Restructuring costs had a negative impact of SEK 1.9 million (0.0). Profit/loss after tax was positively impacted by state subsidies and similar items related to Covid-19 by SEK 0.1 million (0.3) and revaluation of contingent earn-outs for completed acquisitions of SEK 5.6 million (0.0). Basic earnings per share amounted to SEK 0.19 (-0.01) for the quarter.

EBITA for January–September was SEK 82.1 million (30.7). Operating profit/loss was SEK 77.8 million (27.9). Profit/loss after tax was SEK 53.0 million (1.0). Adjusted profit/loss after tax amounted to SEK 58.0 million (8.9). Acquisition costs had a negative impact on profit/loss after tax of SEK 12.5 million (10.0), with SEK 1.8 million (2.2) reported in the item Other external expenses and SEK 10.6 million (7.8) reported in the item Net financial items. Restructuring costs had a negative impact of SEK 1.9 million (0.0). The Net financial items was positively impacted by currency effects from the revaluation of balance sheet items. Profit/loss after tax was positively impacted by state subsidies and similar items related to Covid-19 by SEK 3.8 million (2.1) and revaluation of contingent earn-outs for completed acquisitions of SEK 5.6 million (0.0). Basic earnings per share amounted to SEK 0.30 (0.01) for January–September.




Financial position

Equity and equity ratio

Equity at the end of the period totaled SEK 488.5 million (240.6), equating to SEK 2.71 (1.46) per share outstanding at the end of the period. The equity ratio at the end of the period was 32.3 % (32.6 %).

At the end of the reporting period, the company's equity was entirely attributable to the shareholders of the parent company.



Cash and cash equivalents and short-term investments

Cash and cash equivalents at the end of the period totaled SEK 124.0 million (139.8). At the end of the period, the Group had an overdraft facility of SEK 54.4 million (18.1), which was utilized in the amount of SEK 2.1 million (9.3). At the end of the period, the Group had no short-term investments.

Net debt

Net debt at the end of the period totaled SEK 435.7 million (182.7). The ratio of interest-bearing net debt to EBITDA at the end of the period was 3.8 (3.4). This ratio was calculated as at September 30, 2022, using the rolling 12-month EBITDA, from October 2021 up to and including September 2022. With pro forma rolling 12-month EBITDA, the ratio would have been 2.8 at the end of the period.

One of the Group's long-term financial targets is for the ratio of interest-bearing net debt to EBITDA not to exceed 3.

EBITDA according to the Group's definition of net debt in relation to EBITDA is not calculated pro forma. This means that the key ratio as of the end of the period is affected by the fact that most of the year's acquisitions and the previous year's acquisitions have not contributed EBITDA throughout the full 12 month period, which means that net debt in relation to EBITDA is increased. Pro forma EBITDA for 12 months, from October 2021 up to and including September 2022 amounted to SEK 154.6 million, but the key ratio uses EBITDA SEK 114.1 million.

At the end of the period, loans and other

interest-bearing liabilities due for repayment within one year totaled SEK 29.2 million (50.4). Loans and other interest-bearing liabilities due for repayment within one year include a bank loan of SEK 14.0 million (14.9), pledged trade receivables of SEK 0.0 million (18.1), utilized overdraft facilities of SEK 2.1 million (9.3) and lease liabilities of SEK 13.1 million (6.6). At the end of the comparison period, liabilities relating to deferred payment of tax as a result of Covid-19 was SEK 1.2 million. Overdraft facilities are classified as short-term borrowing, but this portion of short-term borrowing is continuously refinanced. During 2022, the Group has reduced the amount of pledged trade receivables for companies that are part of the Group cash pool.

At the end of the period, loans due for repayment after one year or more totaled SEK 530.5 million (272.5). Loans due for repayment after one year or more include the Group's bond loan of SEK 488.5 million (243.2), a bank loan of SEK 0.9 million (1.0) and lease liabilities of SEK 41.1 million (28.3). The increase in lease liabilities is partly attributable to recently acquired subsidiaries.

Bond term sheet net debt

The bond loan issued by ADDvise in May 2021 is subject to conditions linked to indebtedness. A calculation is made of net debt in relation to EBITDA. The definition of net debt and EBITDA in the bond term sheet is different from the Group's key performance indicators. For the calculation of net debt and EBITDA in accordance with the terms of the bond, please refer to *Definition of key performance indicators*.

Cash flow

Operating cash flow for quarter was SEK 8.2 million (-8.7). During the comparison period, ADDvise paid off liabilities of SEK 0.8 million relating to deferred payment of tax as a result of Covid-19. The effect of the payment of this deferral is reported in the consolidated statement of cash flows under operating cash flow.

Operating cash flow for January–September was SEK 8.0 million (-16.9). During the comparison period, ADDvise paid off liabilities of SEK 11.5 million relating to deferred payment of tax as a result of Covid-19. The effect of the payment of this deferral is reported in the consolidated statement of cash flows under operating cash flow.

Cash flow from Operations for the quarter amounted to SEK 20.8 million. During the quarter, cash flow from Operations was negatively affected by increased working capital, including higher inventory levels. Cash flow from Operations for January–September amounted to SEK 42.9 million. Cash flow from Operations includes investments in fixed assets and amortization of lease liabilities. Comparative figures have not been calculated, as 2020 and 2021 have been affected by the covid-19 pandemic to a greater extent than 2022. A comparison

would therefore reflect the effects of the pandemic and not only developments in business operations.

As of the interim report for January–March 2022, cash flow from Operations is presented, which is cash flow from the Group's business operations, and where items attributable to acquisition activities having an impact on cash flow have been eliminated. For the calculation of cash flow from Operations, see *Definition of key performance indicators*.

Cash flow for the quarter totaled SEK 15.1 million (23.7). No acquisitions were completed during the quarter. Injections of cash and cash equivalents from the acquired companies at the time of consolidation of the new acquisitions in the Group totaled SEK 4.2 million (1.8) in the condensed consolidated statement of cash flow, after updates to the preliminary purchase price allocations.

Cash flow for January–September totaled SEK -208.3 million (98.9). The acquisitions of JTECH Medical, Poly Pharma, Seebreath and Surplus Diabetics were completed during the period. Injections of cash and cash equivalents from the acquired companies at the time of consolidation of the new acquisitions in the Group totaled SEK 8.5 million (12.7) during the period. During the period, ADDvise received SEK 100.0 million before issue costs in connection with the issue of new class B shares. For further information, see *Significant events during the reporting period*.

Intangible non-current assets

The change in goodwill during the quarter was SEK 2.4 million (123.4). The change in trademarks was SEK -3.1 million (13.4).

The change in goodwill during January–September was SEK 286.1 million (140.6). The change in trademarks was SEK 185.3 million (24.2).

For information about goodwill and trademarks attributable to acquisitions during this year, see *Note 5 Business combinations*.

Intangible non-current assets other than goodwill and trademarks account for the majority of capitalized expenditure for development work and similar activities. Investments in capitalized expenditure for development work and similar activities during the quarter totaled SEK 1.8 million (-0.4). Investments in capitalized expenditure for development work and similar activities during January–September totaled SEK 5.7 million (1.4).

Investments in intangible non-current assets other than goodwill, trademarks and capitalized expenditure for development work and similar activities during the quarter totaled SEK 0.0 million (0.0). Investments in intangible non-current assets other than goodwill, trademarks and capitalized expenditure for development work and similar activities during January–September totaled SEK 0.3 million (0.3).

Property, plant and equipment

Investments in property, plant and equipment during the quarter totaled SEK 3.5 million (5.7). Investments in property, plant and equipment during January–September totaled SEK 8.5 million (17.5). Investments in property, plant and equipment include leased non-current assets in accordance with IFRS 16 Leases.

Acquisitions 2022

The table shows acquisitions completed in 2022. Net revenue and EBITDA in the table are estimates of annual rates from the time of the acquisition using local accounting principles. For further information on the acquisitions, see *Note 5 Business combinations*.

Acquisition	Consolidated from	Business unit	Net revenue 12 months	EBITDA 12 months
JTECH Medical	March	Healthcare	USD 3.2 million	USD 1.1 million
Poly Pharmaceuticals	February	Healthcare	USD 8.3 million	USD 2.0 million
Seebreath	May	Healthcare	SEK 12.0 million	SEK 8.0 million
Surplus Diabetics	April	Healthcare	USD 18.1 million	USD 3.2 million

Parent company

Net revenue and profit/loss

Net revenue at the parent company for the quarter totaled SEK 4.0 million (7.1). Operating profit/loss was SEK -3.3 million (1.6). The net profit/loss was SEK 41.9 million (-6.1).

Net revenue at the parent company for January–September totaled SEK 16.1 million (17.3). Operating profit/loss was SEK -7.7 million (0.6). The net profit/loss was SEK 22.7 million (-18.5).

Equity

The balance sheet total was SEK 954.7 million (581.5), of which equity constituted SEK 341.2 million (205.4).

Significant events during the reporting period

ADDvise completes a directed new share issue of approximately SEK 100 million

On March 14, 2022, ADDvise carried out a directed new share issue of 15,384,616 shares of series B, corresponding to approximately SEK 100 million. Through the directed new share issue ADDvise received approximately SEK 100 million before issue costs. Through the directed new share issue, the number of outstanding shares increased by 15,384,616 shares, from 165,107,273 shares to 180,491,889 shares. The share capital increased by SEK 1,538,461.6,

from SEK 16,510,727.3 to SEK 18,049,188.9. The directed new share issue entailed a dilution of approximately 8.5 percent of the number of shares and 6.2 percent of the number of votes in the company based on the number of shares and votes following the directed new share issue.

The subscription price in the directed new share issue was SEK 6.50. The subscription price per share of series B in the directed new share issue constituted a discount of approximately 5.9 percent compared to the closing price on Nasdaq First North Premier Growth Market on March 14, 2022 and a premium of approximately 0.9 percent to the VWAP during the last five trading days.

Bondholders approve amendment to bond terms and conditions

In January 2022, ADDvise successfully conducted the written procedure initiated on December 16, 2021 regarding the Company's up to SEK 500 million senior covered bond loan with ISIN SE0015222088. The company asked for bondholders' approval for certain changes to bond terms. A sufficient number of bondholders participated in the written procedure in order to form a quorum, and a requisite majority of the bondholders voted in favour to approve the proposal.

ADDvise acquired JTECH Medical, Poly Pharmaceuticals Inc, Seebreath AB and Surplus Diabetics Inc

ADDvise acquired 100% of the shares in the following companies during the period:

- » Poly Pharmaceuticals Inc. Acquisition completed on February 18, 2022.
- » JTECH Medical. Acquisition completed on March 3, 2022.
- » Surplus Diabetics Inc. Acquisition completed on April 19, 2022
- » Seebreath AB. Acquisition completed on May 16, 2022.

ADDvise signed Letter of Intent to acquire CliniChain Holding BV

In September, 2022, ADDvise signed a Letter of Intent with the shareholders of CliniChain Holding BV (CliniChain) regarding an acquisition of 100 percent of the shares in CliniChain.

CliniChain is an international medtech equipment provider for clinical studies. CliniChain is based in Almere, Netherlands. The revenue for the last twelve months as of June 30, 2022, amounted to EUR 8.4 million, of which recurring revenue accounted for 63.9 percent, with an adjusted EBITDA of EUR 4.6 million, corresponding to an adjusted EBITDA margin of 55.0 percent.

The purchase price for CliniChain amounts to a total of EUR 33.8 million, divided into an initial payment of EUR 28.3 million consisting of EUR 22.7 million in cash and a

promissory note of EUR 5.6 million, and one potential earn-out of maximum EUR 5.5 million. The acquisition will be financed with own funds and loan. ADDvise assesses that the acquisition will have a positive impact on ADDvise's earnings per share during the financial year 2023.

The acquisition is subject to a due diligence and that the parties agree to enter into a share purchase agreement. The share purchase agreement and completion of the acquisition is scheduled to be completed during Q4, 2022. At the time of the publishing of this interim report, ADDvise has not completed the acquisition of CliniChain, and is not able to provide a purchase price allocation.

Major customer contracts and orders during the reporting period

- » Order from Design Infinity LCC, a Dubai based pharmaceutical industry interior design contractor, for design and installation of a cleanroom facility for the Himalaya Drug Company based in United Arab Emirates. Order value USD 1.1 million. Delivery is scheduled for 2022.
- » Allocation decision from Region Stockholm-Gotland for delivery of blood specimen collection equipment during a four-year period starting in 2022. Total value SEK 44.0 million.
- » Order from Signature Healthcare Consulting Services, LLC, a group providing personalized medical services in primary care, specialty care and hospital care, for systems for vital signs monitoring, in 110 nursing homes. Order value USD 2.0 million. Delivery is scheduled for 2022.
- » Order from Cadwell Industries, a company specialized in electrodes, consumables, supplies, and accessories for neurology, for wires for electrodiagnostic supplies. Order value USD 1.7 million. Delivery is scheduled for 2022 and 2023.
- » Allocation decision from Helsinki University Hospital in Finland regarding digital x-ray equipment. Order value EUR 2.4 million. Delivery is scheduled for 2022 and 2023.
- » Order from Hortman Health Care Investment LLC, an investment company in the private healthcare sector, based in the United Arab Emirates for design and installation of a stem cell laboratory for a clinic in Dubai, United Arab Emirates. Order value USD 0.6 million. Delivery is scheduled for 2023.

Major shareholder issues call options

On January 10, 2022, the ADDvise board of directors was informed that one of ADDvise's major shareholders, Per Åhlgren through GoMobile nu Aktiebolag, has issued call options in ADDvise to board members, senior executives

and certain other employees in ADDvise Group. In total, 3,696,666 call options have been issued to eleven persons.

Each call option has been issued at a price of SEK 0.45, which corresponds to the market value based on a Black & Scholes valuation, and gives the holder the right to during the period October 9, 2022 – January 9, 2023 acquire one share of series B in ADDvise at a price of SEK 9.55.

ADDvise has not participated in the issuance of these call options and will not incur any costs as a result of such issuance.

Significant events after the reporting period

There are no significant events to report after the reporting period.

Additional information

Employees

The number of employees at the end of the reporting period was 334 (252).

Pro forma profit/loss

The numbers in the *Pro forma rolling 12 months Oct 2021–Sep 2022* column on the first page are pro forma numbers and have not been reviewed by the company's auditor. The numbers are for October 2021 – September 2022 including all acquisitions in the period after October 1, 2021, until the publication of this report.

Financial targets

The Board of ADDvise has adopted short-term and long-term financial targets.

Short-term financial targets

In the light of the company's continued progress, the Board of Directors of ADDvise have decided to raise the 2022 EBITDA target from the previous target communicated on 23 September 2021. The target was raised on April 7, 2022. For the financial year 2022, rolling 12 months pro forma basis, ADDvise expects to reach an EBITDA of at least SEK 200 million before acquisition costs (adjusted EBITDA).

The previous EBITDA target was at least SEK 150 million on a pro forma basis for 2022. The earlier communicated revenue target of SEK 1 billion in net sales on a pro forma basis before the end of 2022 remains unchanged.

Long-term financial targets

The targets are a level of ambition to be achieved over several years. These targets will be achieved through a combination of organic growth and acquisitions. The targets are divided into four areas: growth, profitability, capital structure and dividend.

- » Growth: ADDvise must have annual revenue growth of at least 25%. Growth will be achieved organically as well as through acquisitions.
- » Profitability: ADDvise will aim to achieve an EBITDA margin of 20%.
- » Capital structure: ADDvise's ratio of interest-bearing net debt to EBITDA must not exceed 3.0.
- » Dividend: 25% of the preceding year's profit, excluding the revaluation of additional purchase considerations, will be distributed to the shareholders.

Sustainability

ADDvise's business concept is to improve, extend and save people's lives. It is a social responsibility that contributes to a more sustainable society. But sustainability for us is more than that. It's about taking responsibility and make a difference at all levels. When we talk about sustainability, we mean sustainable for the environment, sustainable from a social perspective and sustainable from a business perspective. Together with our subsidiaries, we we can do great good.

Sustainability is becoming increasingly fundamental in our pursuit of better business results. In 2022, we will continue to work on developing and improving our sustainability work.

ADDvise has been reporting sustainability-related information to Nasdaq since 2021 and is certified as a Nasdaq ESG Transparency partner. ESG stands for Environment, Social, and Governance and is a long-term effort to reduce negative impacts and increase positive impacts in areas. We strive to increase the amount of reported data and improve our impact.

Sustainability goals by 2030

ADDvise's long-term sustainability goals have a clear connection to the company's vision of contributing to a sustainable society through products and services that improve, prolong and save people's lives.

The sustainability goals, in combination with the financial goals, will ensure that the company steers towards long-term profitable and sustainable growth.

Environment

- » Reduce the carbon dioxide intensity by 50 %.

Finance / Governance

- » All companies within the Group must have incentives linked to sustainability-related goals.
- » 100 % of the acquisitions must contribute to the UN's sustainability goal no. 3 good health and well-being and meet the requirements of ADDvise policy for sustainable investments.
- » 1.5 % of net sales will be set aside for product development of products that improve, prolong, and save people's lives.

Social

- » Achieve gender equality of people on the board and in senior positions (males and females are represented in the range 40–60 %).
- » All companies within the Group must comply with a code of conduct.
- » Sick leave max 5%.
- » Our vision is to work towards Zero workplace accidents.

Condensed consolidated statement of comprehensive income

SEK thousands	2022 Jul-Sep ¹	2021 Jul-Sep ²	2022 Jan-Sep ¹	2021 Jan-Sep ²	2021 Jan-Dec ²	2020 Jan-Dec
Net revenue	236,960	105,557	631,260	310,939	465,953	358,487
Capitalized work on own account	1,852	74	5,744	1,891	2,659	769
Other operating income	5,376	81	6,174	203	498	7,712
	244,188	105,712	643,177	313,032	469,110	366,968
Cost of materials	-101,452	-51,190	-271,235	-167,599	-252,047	-221,154
Other external expenses	-46,048	-11,463	-121,120	-30,219	-47,334	-27,060
Personnel costs	-56,641	-29,790	-155,574	-77,119	-112,468	-70,929
Depreciation and amortization	-6,374	-3,720	-16,954	-9,975	-13,716	-11,967
Other operating expenses	-869	3	-540	-193	0	-1,600
	-211,384	-96,160	-565,423	-285,106	-425,564	-332,711
Operating profit/loss (EBIT)	32,803	9,552	77,754	27,926	43,546	34,257
Net financial items	9,788	-10,213	-14,630	-24,361	-35,888	-16,400
Profit/loss before tax (EBT)	42,591	-661	63,124	3,566	7,658	17,857
Tax	-8,690	-903	-10,103	-2,539	-4,853	-3,219
Profit/loss for the period	33,901	-1,564	53,021	1,027	2,805	14,637
Profit/loss attributable to:						
Shareholders of the parent company	33,901	-1,564	53,021	1,027	2,805	14,638
Non-controlling interests	-	-	-	-	-	-1
	33,901	-1,564	53,021	1,027	2,805	14,637
Other comprehensive income						
Foreign exchange differences on the translation of foreign operations for the period	61,552	5,867	92,800	7,697	12,783	-7,729
Change in value of financial assets measured at fair value through other comprehensive income for the period	0	0	0	-122	-122	122
Comprehensive income for the period	95,453	4,303	145,821	8,602	15,466	7,030
Comprehensive income attributable to:						
Shareholders of the parent company	95,453	4,303	145,821	8,602	15,466	7,028
Non-controlling interests	-	-	-	-	-	2
	95,453	4,303	145,821	8,602	15,466	7,030
Basic earnings per share, SEK ³	0.19	-0.01	0.30	0.01	0.02	0.12
Diluted earnings per share, SEK ³	0.19	-0.01	0.30	0.01	0.02	0.10

Note 1: Companies acquired in 2022 are consolidated in the ADDvise Group from: Poly Pharmaceuticals Inc February 12, 2022. JTECH Medical March 3, 2022. Surplus Diabetics Inc April 19, 2022. Seebreath AB May 16, 2022.

Note 2: Companies acquired in 2021 are consolidated in the ADDvise Group from: MRC Systems FZE March 28, 2021. MediSuite LLC August 4, 2021. Graham Medical Technologies LLC September 15, 2021. Southern Life Systems Inc November 24, 2021.

Note 3: Earnings per share were adjusted to take into account the outcome of warrants in series 2019/2021 in February 2021, the directed share issue in September 2021 and the directed share issue in March 2022.

Condensed consolidated statement of financial position

SEK thousands	2022 Sep 30	2021 Sep 30	2021 Dec 31	2020 Dec 31
ASSETS				
<i>Non-current assets</i>				
Goodwill	574,694	296,885	288,559	156,319
Trademarks	313,103	46,844	127,767	22,594
Other intangible non-current assets	46,193	19,025	24,615	19,491
Property, plant and equipment	78,296	54,128	65,072	15,944
Non-current financial assets	318	229	232	134
Contract assets	13,325	-	14,119	-
Deferred tax assets	0	3,282	0	7,122
<i>Total non-current assets</i>	<i>1,025,929</i>	<i>420,393</i>	<i>520,364</i>	<i>221,604</i>
<i>Current assets</i>				
Inventories	114,349	61,224	66,543	33,422
Contract assets	93,068	33,944	48,367	727
Trade receivables	130,800	74,880	96,808	44,930
Other current receivables	26,421	8,824	11,625	5,454
Short-term investments ¹	0	0	0	0
Cash and cash equivalents	123,977	139,845	325,735	39,606
<i>Total current assets</i>	<i>488,616</i>	<i>318,717</i>	<i>549,078</i>	<i>124,140</i>
TOTAL ASSETS	1,514,544	739,110	1,069,442	345,743
EQUITY AND LIABILITIES				
<i>Equity</i>	<i>488,512</i>	<i>240,609</i>	<i>247,275</i>	<i>91,049</i>
Equity attributable to:				
Shareholders of the parent company	488,512	240,609	247,275	90,966
Non-controlling interests	-	-	-	83
	488,512	240,609	247,275	91,049
<i>Non-current liabilities</i>				
Interest-bearing liabilities ¹	530,481	272,504	525,145	142,442
Deferred tax liabilities	74,476	0	14,702	0
Other non-current liabilities	127,728	65,494	108,023	0
<i>Total non-current liabilities</i>	<i>732,685</i>	<i>337,998</i>	<i>647,870</i>	<i>142,442</i>
<i>Current liabilities</i>				
Interest-bearing liabilities	29,181	50,073	29,044	50,930
Current tax liabilities	18,803	5,128	9,797	2,145
Contract liabilities	24,115	5,564	13,610	1,303
Trade payables	92,025	46,187	60,329	29,073
Other current liabilities	129,223	53,551	61,516	28,801
<i>Total current liabilities</i>	<i>293,347</i>	<i>160,503</i>	<i>174,296</i>	<i>112,252</i>
TOTAL EQUITY AND LIABILITIES	1,514,544	739,110	1,069,442	345,743

Note 1 As at December 31, 2020, the nominal value of the holding of own bonds was SEK 1,110 thousand and the fair value was SEK 1,088 thousand. The holding has been offset against the liability for the bond loan, which is recognized at a net amount that reflects ADDvise's expected cash flow upon settlement of the financial instrument, since the asset and liability were to be settled simultaneously. The financial instruments were settled in June 2021.

Condensed consolidated statement of changes in equity

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Opening equity	393,059	118,774	247,275	91,049	91,049	84,142
Profit/loss for the period	33,901	-1,564	53,021	1,027	2,805	14,637
Other comprehensive income for the period	61,552	5,867	92,800	7,575	12,661	-7,607
Comprehensive income for the period	95,453	4,303	145,821	8,602	15,466	7,030
New share issue	0	117,428	95,416	143,648	143,449	-123
Dividends	0	0	0	-2,794	-2,794	0
Change in non-controlling interests	0	104	0	104	104	0
Translation reserve	0	0	0	0	0	0
Closing equity	488,512	240,609	488,512	240,609	247,275	91,049
Attributable to:						
Shareholders of the parent company	488,512	240,609	488,512	240,609	247,275	90,966
Non-controlling interests	-	-	-	-	-	83
Total equity	488,512	240,609	488,512	240,609	247,275	91,049

Condensed consolidated statement of cash flows

SEK thousands	2022 Jul-Sep	2021 Jul-Sep ¹	2022 Jan-Sep	2021 Jan-Sep ¹	2021 Jan-Dec ¹	2020 Jan-Dec ²
Operating activities						
Profit/loss before tax	42,591	-661	63,124	3,566	7,658	17,857
Adjustments for non-cash items	-23,648	5,235	-25,092	10,510	9,469	3,778
Income tax paid	-2,532	-261	-4,077	-800	-85	-2,259
Operating cash flow before changes in working capital	16,411	4,313	33,955	13,275	17,042	19,375
Operating cash flow	8,196	-8,663	7,980	-16,876	10,186	57,438
Investing cash flow ³	3,627	-100,392	-349,070	-134,659	-201,662	-7,214
Financing cash flow	3,268	132,778	132,802	250,388	473,975	-23,314
Cash flow for the period	15,091	23,723	-208,287	98,854	282,499	26,910
Cash and cash equivalents at start of period	104,997	115,495	325,735	39,606	39,606	13,259
Foreign exchange differences in cash and cash equivalents	3,889	627	6,530	1,385	3,629	-562
Cash and cash equivalents at end of period	123,977	139,845	123,977	139,845	325,735	39,606

Note 1 During the period July–September 2021, ADDvise paid liabilities of SEK 0.8 million relating to deferred payment of taxes and charges as a result of the Covid-19 situation. During the period January–September 2021, ADDvise paid liabilities of SEK 11.5 million relating to deferred payment of taxes and charges as a result of the Covid-19 situation. During the period January–December 2021, ADDvise paid liabilities of SEK 12.6 million relating to deferred payment of taxes and charges as a result of the Covid-19 situation. The effect of payment of this deferral is reported in the consolidated statement of cash flows under operating cash flow for July–September 2021, January–September 2021 and January–December 2021.

Note 2 During the period April–December 2020, deferred payment of taxes and charges of SEK 12.6 million was granted because of the Covid-19 situation. The liability for deferred payment at the end of 2020 was SEK 12.6 million. The effect of this deferral is reported in the consolidated statement of cash flows under operating cash flow for January–December 2020.

Note 3 For details on the reporting of the net outflow of cash and cash equivalents relating to acquisitions, see *Note 5 Business combinations*.

Consolidated income statement for five quarters

SEK thousands	2022 Jul-Sep	2022 Apr-Jun	2022 Jan-Mar	2021 Oct-Dec	2021 Jul-Sep
Net revenue	236,960	231,903	162,397	155,014	105,557
Capitalized work on own account	1,852	1,177	2,715	768	74
Other operating income	5,376	746	52	295	81
	244,188	233,826	165,163	156,078	105,712
Cost of materials	-101,452	-91,973	-77,810	-84,448	-51,190
Other external expenses	-46,048	-54,908	-20,165	-17,115	-11,463
Personnel costs	-56,641	-53,346	-45,587	-35,349	-29,790
Other operating expenses	-869	704	-375	193	3
	-205,010	-199,523	-143,937	-136,718	-92,440
EBITDA	39,177	34,304	21,227	19,360	13,272
EBITDA margin, %	16.5%	14.8%	13.1%	12.5%	12.6%
Depreciation and amortization	-6,374	-5,805	-4,774	-3,740	-3,720
Operating profit/loss (EBIT)	32,803	28,498	16,452	15,620	9,552
Operating margin, %	13.8%	12.3%	10.1%	10.1%	9.0%
Net financial items	9,788	-8,541	-15,876	-11,527	-10,213
Profit/loss before tax (EBT)	42,591	19,957	576	4,092	-661
Tax	-8,690	-907	-506	-2,314	-903
Profit/loss for the period	33,901	19,050	70	1,778	-1,564
Profit/loss attributable to:					
Shareholders of the parent company	33,901	19,050	70	1,778	-1,564
Non-controlling interests	-	-	-	-	-
	33,901	19,050	70	1,778	-1,564

Key performance indicators

SEK thousands	2022 Jul-Sep ¹	2021 Jul-Sep ²	2022 Jan-Sep ¹	2021 Jan-Sep ²	2021 Jan-Dec ²	2020 Jan-Dec
Net revenue	236,960	105,557	631,260	310,939	465,953	358,487
Gross margin, %	57.2%	51.5%	57.0%	46.1%	45.9%	38.3%
EBITDA	39,177	13,272	94,708	37,902	57,261	46,224
EBITDA margin, %	16.5%	12.6%	15.0%	12.2%	12.3%	12.9%
Adjusted EBITDA	35,991	14,510	89,050	38,026	57,058	33,315
Adjusted EBITDA margin, %	15.2%	13.7%	14.1%	12.2%	12.2%	9.3%
EBITA	34,424	10,497	82,107	30,742	46,797	38,147
EBITA margin, %	14.5%	9.9%	13.0%	9.9%	10.0%	10.6%
Operating profit/loss (EBIT)	32,803	9,552	77,754	27,926	43,546	34,257
Operating margin, %	13.8%	9.0%	12.3%	9.0%	9.3%	9.6%
Profit/loss before tax (EBT)	42,591	-661	63,124	3,566	7,658	17,857
Net margin, %	18.0%	-0.6%	10.0%	1.1%	1.6%	5.0%
Profit/loss for the period	33,901	-1,564	53,021	1,027	2,805	14,637
Adjusted profit/loss for the period	31,437	3,025	58,008	8,947	12,739	1,894
Equity ratio, %	32.3%	32.6%	32.3%	32.6%	23.1%	26.3%
Net debt	-435,685	-182,732	-435,685	-182,732	-228,455	-153,766
Net debt-to-EBITDA	3.8	3.4	3.8	3.4	4.0	3.3
Number of employees at end of period	334	252	334	252	285	108
Equity per share in SEK	2.71	1.46	2.71	1.46	1.50	0.94
Basic earnings per share in SEK ³	0.19	-0.01	0.30	0.01	0.02	0.12
Diluted earnings per share in SEK ³	0.19	-0.01	0.30	0.01	0.02	0.10
Number of shares at end of period	180,491,889	165,107,273	180,491,889	165,107,273	165,107,273	96,913,631
Average number of shares before dilution	180,491,889	146,052,394	176,434,408	135,728,795	143,133,781	96,913,631
Average number of shares after dilution	180,491,889	146,052,394	176,434,408	135,728,795	143,133,781	113,133,907

Note 1: Companies acquired in 2022 are consolidated in the ADDvise Group from: Poly Pharmaceuticals Inc February 12, 2022. JTECH Medical March 3, 2022. Surplus Diabetics Inc April 19, 2022. Seebreath AB May 16, 2022.

Note 2: Companies acquired in 2021 are consolidated in the ADDvise Group from: MRC Systems FZE March 28, 2021. MediSuite LLC August 4, 2021. Graham Medical Technologies LLC September 15, 2021. Southern Life Systems Inc November 24, 2021.

Note 3: Earnings per share were adjusted to take into account the outcome of warrants in series 2019/2021 in February 2021, the directed share issue in September 2021 and the directed share issue in March 2022.

Condensed parent company income statement

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Net revenue	3,951	7,130	16,071	17,329	24,814	19,448
Capitalized work on own account	0	0	0	0	0	0
Other operating income	0	0	0	0	0	0
	3,951	7,130	16,071	17,329	24,814	19,448
Cost of materials	0	0	0	0	0	0
Other external expenses	-2,511	-1,525	-9,443	-5,462	-8,479	-5,932
Personnel costs	-4,719	-3,938	-14,207	-11,170	-14,601	-11,850
Depreciation and amortization	-49	-48	-160	-130	-181	-306
Other operating expenses	0	0	0	0	-9	-1
	-7,279	-5,510	-23,810	-16,761	-23,271	-18,090
Operating profit/loss (EBIT)	-3,329	1,620	-7,739	568	1,543	1,358
Net financial items	45,201	-6,707	30,448	-18,103	-21,933	1,164
Profit/loss after financial items (EBT)	41,872	-5,087	22,709	-17,535	-20,390	2,522
Appropriations	0	-1,000	0	-1,000	21,550	11,330
Tax	0	0	7	0	-1,807	-1,829
Profit/loss for the period	41,872	-6,087	22,716	-18,535	-647	12,024
Parent company statement of comprehensive income						
Profit/loss for the period	41,872	-6,087	22,716	-18,535	-647	12,024
Other comprehensive income for the period	0	0	0	0	0	0
Comprehensive income for the period	41,872	-6,087	22,716	-18,535	-647	12,024

Condensed parent company balance sheet

SEK thousands	2022 Sep 30	2021 Sep 30	2021 Dec 31	2020 Dec 31
ASSETS				
<i>Non-current assets</i>				
Intangible non-current assets	276	246	323	181
Property, plant and equipment	305	204	281	154
Non-current financial assets	413,299	375,201	379,734	212,971
Deferred tax assets	10,522	12,329	10,522	12,329
<i>Total non-current assets</i>	<i>424,403</i>	<i>387,981</i>	<i>390,860</i>	<i>225,636</i>
<i>Current assets</i>				
Other current receivables	464,787	80,935	141,549	40,767
Short-term investments ¹	0	0	0	0
Cash and bank balances	65,503	112,595	286,161	11,484
<i>Total current assets</i>	<i>530,291</i>	<i>193,530</i>	<i>427,710</i>	<i>52,251</i>
TOTAL ASSETS	954,693	581,511	818,570	277,887
EQUITY AND LIABILITIES				
<i>Equity</i>	<i>341,233</i>	<i>205,411</i>	<i>223,101</i>	<i>83,093</i>
<i>Non-current liabilities</i>				
Interest-bearing liabilities ¹	488,481	243,205	487,146	135,337
Other non-current liabilities	31,501	52,966	54,488	0
<i>Total non-current liabilities</i>	<i>519,982</i>	<i>296,171</i>	<i>541,634</i>	<i>135,337</i>
<i>Current liabilities</i>				
Interest-bearing liabilities	0	0	0	11,500
Current tax liabilities	605	851	865	850
Trade payables	1,741	1,168	4,473	1,555
Other current liabilities	91,132	77,909	48,496	45,552
<i>Total current liabilities</i>	<i>93,478</i>	<i>79,928</i>	<i>53,834</i>	<i>59,457</i>
TOTAL EQUITY AND LIABILITIES	954,693	581,511	818,570	277,887

Note 1 As at December 31, 2020, the nominal value of the holding of own bonds was SEK 1,110 thousand and the fair value was SEK 1,088 thousand. The holding has been offset against the liability for the bond loan, which is recognized at a net amount that reflects ADDvise's expected cash flow upon settlement of the financial instrument, since the asset and liability were to be settled simultaneously. The financial instruments were settled in June 2021.

Notes

Note 1 Information about the company

ADDvise Group AB (publ), company registration number 556363-2115, with its registered office in Stockholm, Sweden.

In this report, ADDvise Group AB (publ) is referred to either using its full name or as the "parent company", while the ADDvise Group is referred to as "ADDvise" or the "Group." All amounts are expressed in thousands of Swedish kronor (SEK thousands) unless otherwise indicated.

Note 2 Accounting policies

The report was prepared in accordance with IAS 34 Interim financial reporting and the relevant sections of the Swedish Annual Accounts Act. The accounting policies and bases of calculation applied are the same as in the most recent annual report.

The parent company's report was prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act. The accounting policies and bases of calculation applied are the same as in the most recent annual report.

Note 3 Related party transactions

ADDvise Board member Erland Pontusson invoiced the company for consultancy services during the period.

Note 4 Segment reporting

ADDvise's segment information is presented from the company management's perspective, with operating segments identified based on internal reporting to the company's chief operating decision maker. The CEO is ADDvise's chief operating decision maker.

ADDvise's operating segments comprise two business units: Lab and Healthcare. This classification reflects the company's internal organization and reporting system. Internal pricing is on market terms. Intra-Group profits are eliminated.

As of the interim report for January–March 2022 and going forward, acquisition costs and other items attributable to acquisitions are no longer allocated to the business units. This means that the segment's EBITDA is recognized excluding acquisition costs and other items attributable to acquisitions. In the table below, acquisition costs are reported on the line Acquisition costs in Other external expenses. Other items attributable to acquisitions, such as revaluations of liabilities for contingent earn-outs for completed acquisitions, are recognized on the lines Unallocated Group income and Unallocated Group expenses. Comparative figures have been restated for comparative periods in 2021 and for the full year 2020.

Unallocated Group expenses include, for example, costs for parent company functions. These costs are offset here against the management fees and service fees received by the parent company, which means that the net figure can be positive.

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Lab business unit	69,494	49,932	196,925	153,903	217,162	151,043
Healthcare business unit	167,465	55,625	434,334	157,035	248,791	207,444
Total external net revenue	236,960	105,557	631,260	310,939	465,953	358,487
Lab business unit	2,853	6,613	15,147	19,382	26,275	17,278
Healthcare business unit	39,900	6,528	89,381	19,424	32,034	20,794
Total operating profit/loss before depreciation and amortization (EBITDA)	42,752	13,141	104,528	38,806	58,309	38,072
Acquisition costs in Other external expenses	-649	-1,559	-1,841	-2,203	-2,798	-196
Unallocated Group income	5,565	0	5,565	0	0	7,429
Unallocated Group expenses	-8,491	1,689	-13,545	1,299	1,751	919
Depreciation and amortization	-6,374	-3,719	-16,954	-9,975	-13,716	-11,967
Net financial items	9,788	-10,213	-14,630	-24,361	-35,888	-16,400
Consolidated profit/loss before tax (EBT)	42,591	-661	63,124	3,566	7,658	17,857

Note 5 Business combinations

During the reporting period January–September, 2022, four acquisitions were completed: JTECH Medical (JTECH), Poly Pharmaceuticals Inc (Poly Pharma), Seebreath AB (Seebreath) and Surplus Diabetics Inc (Surplus Diabetics).

On February 18, 2022, ADDvise completed the acquisition of Poly Pharmaceuticals Inc (Poly Pharma). ADDvise acquired 100 percent of the shares in Poly Pharma. The closing date was February 18, 2022. Poly Pharma is consolidated in the ADDvise Group from February 12, 2022. Poly Pharma is an American pharmaceutical company specializing in developing, manufacturing and marketing over-the-counter generic pharmaceuticals for the treatment of cough, cold, allergy and sinusitis, as well as for urological health and pain relief. Sales are mainly to pharmacies and general practitioners. The company markets and sells 20 proprietary pharmaceuticals in the U.S. market, including Folite, Deconex, Poly Tussin, Alahist and Poly Hist. Poly Pharma is based in Huntsville, Alabama.

On March 3, 2022, ADDvise completed the acquisition of JTECH Medical (JTECH). ADDvise acquired 100 percent of the shares in JTECH. The closing date was March 3, 2022. JTECH is consolidated in the ADDvise Group from March 3, 2022. JTECH is an American medtech company specializing in developing software and instruments to quantify patients' range of motion, pain, and strength in muscles during rehabilitation of muscle disorders. The company's products are primarily used by chiropractors, physicians and physiotherapists. The products are sold globally. JTECH is based in Salt Lake City, Utah. The company's revenue consists partly of license revenue from the software, partly of revenue from the sale of corresponding instruments.

On April 19, 2022, ADDvise completed the acquisition of Surplus Diabetics Inc (Surplus Diabetics). ADDvise acquired 100 percent of the shares in Surplus Diabetics. The closing date was April 19, 2022. The company is consolidated in the ADDvise Group from April 19, 2022. Surplus Diabetics is an American medtech company, specialized in supplying the U.S. market with diabetes products, such as glucose monitors, insulin and test stripes. Sales are made to pharmacies, wholesalers and directly to consumers. Surplus Diabetics is based in Deerfield Beach, Florida.

On May 16, 2022, ADDvise completed the acquisition of Seebreath AB (Seebreath). ADDvise acquired 100 percent of the shares in Seebreath. The closing date was May 16, 2022. The company is consolidated in the ADDvise Group from May 16, 2022. Seebreath is a Swedish medtech company developing and producing colorimetric CO₂-indicating products used in respiratory care. The company's products are FDA approved and sold on the American market through distributors.

Purchase prices

SEK thousands	JTECH Medical	Poly Pharma- ceuticals Inc	Surplus Diabetics Inc	Seebreath AB	Total
Cash	43,174	69,168	144,851	30,732	287,925
Holdback amount	2,427	33,164	2,394	1,500	39,485
Interest-free promissory note	5,824	0	4,789	0	10,612
Earn-outs	14,753	18,579	15,467	8,500	57,300
Total purchase price	66,177	120,912	167,501	40,732	395,322

continuation of Note 5; see next page

Preliminary purchase price allocations

The fair value of the acquired assets has not yet been assessed with certainty. The purchase price allocations presented in this interim report are preliminary only. Finalized purchase price allocations will be determined in time for the 2022 annual report.

SEK thousands	JTECH Medical	Poly Pharmaceuticals Inc	Surplus Diabetics Inc	Seebreath AB	Total
Trademarks	18,751	44,487	110,408	0	173,646
Other intangible non-current assets	0	3	0	17,663	17,666
Property, plant and equipment	686	4,281	1,460	0	6,427
Non-current financial assets	44	6	0	85	135
Deferred tax assets	0	0	0	0	0
Inventories	4,125	4,998	2,206	0	11,328
Contract assets	3,667	0	0	0	3,667
Trade receivables	1,572	12,412	1,323	4,919	20,225
Short-term investments	0	0	0	0	0
Other current receivables	1,237	841	46	404	2,529
Cash and cash equivalents	2,198	3,294	2,869	180	8,542
Deferred tax liabilities	-7,133	-12,234	-32,791	-3,612	-55,770
Other non-current liabilities	0	0	0	0	0
Interest-bearing liabilities	0	-4,227	-1,460	0	-5,688
Current tax liabilities	0	0	0	0	0
Contract liabilities	0	0	0	0	0
Trade payables	-750	-1,269	0	-1,381	-3,400
Other current liabilities	-3,175	-6,302	-7,770	-9	-17,256
Acquired identifiable net assets	21,222	46,290	76,290	18,248	162,051
Goodwill	44,955	74,621	91,212	22,484	233,271
Acquired net assets	66,177	120,912	167,501	40,732	395,322

Revenue and profit from acquisitions

The newly acquired subsidiaries contributed revenues of SEK 176.7 million and a net profit of SEK 45.7 million to the ADDvise Group for the period from the first date of consolidation until September 30, 2022. If the acquisition dates had been at the beginning of the financial year, the newly acquired subsidiaries would have contributed revenues of SEK 267.8 million and a net profit of SEK 50.0 million to the Group for the period January 1–September 30, 2022.

Transaction costs

Transaction costs related to the acquisitions of SEK 12.5 million are recognized during the period January–September 2022 as costs in the consolidated statement of comprehensive income. SEK 1.8 million is reported in Other external expenses and SEK 10.6 million is reported in Net financial items.

Net outflow of cash and cash equivalents – investing activities

Cash outflow for the acquisition of subsidiaries, after deduction of cash and cash equivalents acquired:

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Cash purchase consideration	-1,578	87,619	300,937	125,897	193,218	4,956
Holdback amounts and interest-free promissory notes	0	14,815	50,097	19,068	21,330	0
Cash and cash equivalents acquired	4,155	1,791	8,542	12,717	17,302	0
Net outflow of cash and cash equivalents	-5,733	100,643	342,492	132,248	197,247	4,956

The cash purchase consideration for the period July–September 2022 comprises payments and adjustments of purchase considerations to the former owners of ADDvise's subsidiaries acquired in 2021 and 2022.

The cash purchase consideration for the period January–September 2022 comprises payments to the former owners of JTECH Medical, Poly Pharmaceuticals Inc, Seebreath AB and Surplus Diabetics Inc, and payments and adjustments of purchase considerations to the former owners of ADDvise's subsidiaries acquired before 2022.

The cash purchase consideration for the period July–September 2021 comprises payments to the former owners of MediSuite LLC and Graham Medical Technologies LLC, and January–September 2021 comprises payments to the former owners of MRC Systems FZE, MediSuite LLC and Graham Medical Technologies LLC.

The cash purchase consideration for the period January–December 2021 comprises payments to the former owners of MRC Systems FZE, MediSuite LLC, Graham Medical Technologies LLC and Southern Life Systems Inc.

The cash purchase consideration for the period January–December 2020 comprises payments of additional purchase considerations to the former owners of ADDvise's subsidiaries.

Note 6 Contract assets and contract liabilities

SEK thousands	2022 Sep 30	2021 Sep 30	2021 Dec 31	2020 Dec 31
Assets				
Long-term lease receivables	13,325	-	14,119	-
Total non-current contract assets	13,325	-	14,119	-
Current lease receivables	22,311	-	15,076	-
Accrued income	70,757	33,944	33,291	727
Total current contract assets	93,068	33,944	48,367	727
Trade receivables	130,800	74,880	96,808	44,930
Total assets	237,193	108,824	159,294	45,657
Contract liabilities				
Advances from customers	5,906	328	2,925	473
Deferred income	18,209	5,236	10,685	830
Total contract liabilities	24,115	5,564	13,610	1,303
Total liabilities	24,115	5,564	13,610	1,303

Note 7 Allocation of income

In accordance with IFRS 15 Revenue from Contracts with Customers, income is recognized and allocated to primary geographic markets, principal goods and services and the time of revenue recognition. Geographical allocation of income is also presented based on the domicile of the operations.

Primary geographic markets by segment based on customer domicile

SEK thousands	2022 Jul-Sep			2021 Jul-Sep		
	Lab	Health-care	Total	Lab	Health-care	Total
Sweden	30,177	5,373	35,551	32,092	8,577	40,668
Europe, excluding Sweden	23,483	24,539	48,022	11,644	23,676	35,321
North America	85	134,365	134,450	103	22,925	23,028
Africa	908	0	908	2,986	0	2,986
Asia	14,841	3,151	17,992	3,106	447	3,553
Other	0	37	37	0	0	0
Total	69,494	167,465	236,960	49,931	55,625	105,557

continuation of Note 7; see next page

SEK thousands	2022 Jan-Sep			2021 Jan-Sep		
	Lab	Health-care	Total	Lab	Health-care	Total
Sweden	101,738	18,477	120,215	111,140	27,988	139,128
Europe, excluding Sweden	35,786	76,092	111,878	19,210	63,581	82,791
North America	3,760	332,382	336,142	103	62,905	63,008
Africa	3,008	0	3,008	14,014	6	14,020
Asia	52,634	7,345	59,980	9,437	2,468	11,905
Other	0	37	37	0	87	87
Total	196,925	434,334	631,260	153,903	157,035	310,939

SEK thousands	2021 Jan-Dec			2020 Jan-Dec		
	Lab	Health-care	Total	Lab	Health-care	Total
Sweden	149,867	34,779	184,646	149,855	49,035	198,890
Europe, excluding Sweden	28,426	104,832	133,258	1,188	82,517	83,704
North America	1,308	104,360	105,667	0	70,296	70,296
Africa	14,821	6	14,827	0	0	0
Asia	22,740	4,717	27,457	0	5,463	5,463
Other	0	97	97	0	134	134
Total	217,162	248,791	465,953	151,043	207,444	358,487

Geographic allocation by segment based on domicile of operations

SEK thousands	2022 Jul-Sep			2021 Jul-Sep		
	Lab	Health-care	Total	Lab	Health-care	Total
Sweden	31,163	23,374	54,538	34,237	20,373	54,610
Europe, excluding Sweden	15,534	18,237	33,771	8,989	16,706	25,696
North America	0	125,854	125,854	0	18,546	18,546
Africa	0	0	0	0	0	0
Asia	22,797	0	22,797	6,706	0	6,706
Other	0	0	0	0	0	0
Total	69,494	167,465	236,960	49,932	55,625	105,557

SEK thousands	2022 Jan-Sep			2021 Jan-Sep		
	Lab	Health-care	Total	Lab	Health-care	Total
Sweden	103,258	71,590	174,848	113,709	62,678	176,387
Europe, excluding Sweden	18,475	50,142	68,617	15,812	46,247	62,059
North America	0	312,602	312,602	0	48,110	48,110
Africa	0	0	0	0	0	0
Asia	75,192	0	75,192	24,382	0	24,382
Other	0	0	0	0	0	0
Total	196,925	434,334	631,260	153,903	157,035	310,939

SEK thousands	2021 Jan-Dec			2020 Jan-Dec		
	Lab	Health-care	Total	Lab	Health-care	Total
Sweden	151,252	85,003	236,255	151,043	82,105	233,148
Europe, excluding Sweden	22,320	76,871	99,191	0	66,144	66,144
North America	0	86,917	86,917	0	59,195	59,195
Africa	0	0	0	0	0	0
Asia	43,590	0	43,590	0	0	0
Other	0	0	0	0	0	0
Total	217,162	248,791	465,953	151,043	207,444	358,487

Principal goods/services July–September 2022

SEK thousands	Lab	Healthcare	Total
Sale of goods: furnishings, safety equipment and consumable materials for laboratories and healthcare	25,639	70,011	95,650
Sale of goods: treatment tables/chairs for healthcare	0	17,489	17,489
Sale of goods under construction contracts	42,386	0	42,386
Sale of pharmaceuticals	0	76,746	76,746
Services	1,470	3,220	4,689
Total	69,494	167,465	236,960

Principal goods/services July–September 2021

SEK thousands	Lab	Healthcare	Total
Sale of goods: furnishings, safety equipment and consumable materials for laboratories and healthcare	22,401	38,196	60,598
Sale of goods: treatment tables/chairs for healthcare	0	12,092	12,092
Sale of goods under construction contracts	25,384	0	25,384
Sale of pharmaceuticals	0	2,444	2,444
Services	2,146	2,892	5,039
Total	49,932	55,625	105,557

Principal goods/services January–September 2022

SEK thousands	Lab	Healthcare	Total
Sale of goods: furnishings, safety equipment and consumable materials for laboratories and healthcare	82,184	198,707	280,891
Sale of goods: treatment tables/chairs for healthcare	0	57,332	57,332
Sale of goods under construction contracts	109,038	0	109,038
Sale of pharmaceuticals	0	168,588	168,588
Services	5,704	9,707	15,411
Total	196,925	434,334	631,260

Principal goods/services January–September 2021

SEK thousands	Lab	Healthcare	Total
Sale of goods: furnishings, safety equipment and consumable materials for laboratories and healthcare	76,535	105,037	181,572
Sale of goods: treatment tables/chairs for healthcare	0	41,175	41,175
Sale of goods under construction contracts	69,398	0	69,398
Sale of pharmaceuticals	0	2,444	2,444
Services	7,970	8,379	16,349
Total	153,903	157,035	310,939

continuation of Note 7; see next page

Principal goods/services January–December 2021

SEK thousands	Lab	Healthcare	Total
Sale of goods: furnishings, safety equipment and consumable materials for laboratories and healthcare	102,586	168,738	271,324
Sale of goods: treatment tables/chairs for healthcare	0	58,230	58,230
Sale of goods under construction contracts	103,508	0	103,508
Sale of pharmaceuticals	0	7,352	7,352
Services	11,067	14,471	25,538
Total	217,162	248,791	465,953

Principal goods/services January–December 2020

SEK thousands	Lab	Healthcare	Total
Sale of goods: furnishings, safety equipment and consumable materials for laboratories and healthcare	122,743	142,561	265,304
Sale of goods: treatment tables/chairs for healthcare	0	47,900	47,900
Sale of goods under construction contracts	17,037	4,612	21,648
Sale of pharmaceuticals	-	-	-
Services	11,263	12,372	23,635
Total	151,043	207,444	358,487

Time of revenue recognition July–September 2022

SEK thousands	Lab	Healthcare	Total
Goods and services transferred to customers at a specific point in time	27,109	163,237	190,346
Goods and services transferred to customers over a period of time	42,386	4,229	46,614
Total	69,494	167,465	236,960

Time of revenue recognition July–September 2021

SEK thousands	Lab	Healthcare	Total
Goods and services transferred to customers at a specific point in time	24,548	51,170	75,717
Goods and services transferred to customers over a period of time	25,384	4,455	29,840
Total	49,932	55,625	105,557

Time of revenue recognition January–September 2022

SEK thousands	Lab	Healthcare	Total
Goods and services transferred to customers at a specific point in time	87,888	422,562	510,449
Goods and services transferred to customers over a period of time	109,038	11,773	120,810
Total	196,925	434,334	631,260

Time of revenue recognition January–September 2021

SEK thousands	Lab	Healthcare	Total
Goods and services transferred to customers at a specific point in time	84,505	143,938	228,443
Goods and services transferred to customers over a period of time	69,398	13,097	82,495
Total	153,903	157,035	310,939

Time of revenue recognition January–December 2021

SEK thousands	Lab	Healthcare	Total
Goods and services transferred to customers at a specific point in time	113,653	234,056	347,709
Goods and services transferred to customers over a period of time	103,508	14,735	118,244
Total	217,162	248,791	465,953

Time of revenue recognition January–December 2020

SEK thousands	Lab	Healthcare	Total
Goods and services transferred to customers at a specific point in time	134,006	181,093	315,099
Goods and services transferred to customers over a period of time	17,037	26,351	43,388
Total	151,043	207,444	358,487

Note 8 Fair value disclosures

The table below lists financial instruments measured at fair value, based on the classification in the fair value hierarchy. The different levels are defined as follows:

- » Level 1 – Quoted prices (unadjusted) in active markets
- » Level 2 – Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- » Level 3 – Unobservable inputs for the asset or liability

September 30, 2022			
SEK thousands	Level 1	Level 2	Level 3
Short-term investments	0		
Contingent purchase consideration			107,742
Total	0	0	107,742

September 30, 2021			
SEK thousands	Level 1	Level 2	Level 3
Short-term investments ¹	0		
Contingent purchase consideration			64,175
Total	0	0	64,175

Note 1

As at September 30, 2021, the nominal value of the holding of own bonds was SEK 0 thousand. The bond loan 2017/2022 was redeemed in full in June 2021.

December 31, 2021			
SEK thousands	Level 1	Level 2	Level 3
Short-term investments ¹	0		
Contingent purchase consideration			96,768
Total	0	0	96,768

Note 1

As at December 31, 2021, the nominal value of the holding of own bonds was SEK 0 thousand. The bond loan 2017/2022 was redeemed in full in June 2021.

December 31, 2020			
SEK thousands	Level 1	Level 2	Level 3
Short-term investments ¹	0		
Contingent purchase consideration			-
Total	0	0	0

Note 1

As at December 31, 2020, the nominal value of the holding of own bonds was SEK 1,110 thousand and the fair value was SEK 1,088 thousand. The holding has been offset against the liability for the bond loan in the condensed consolidated statement of financial

continuation of Note 8; see next page

position and on the parent company's condensed balance sheet. The holding of own bonds and the bond loan are recognized at a net amount that reflects ADDvise's expected cash flow upon settlement of the financial instrument, since the asset and liability were to be settled simultaneously. The financial instruments were settled in June 2021.

Fair value description

Short-term investments

Short-term investments, which comprise shares and bonds, are traded on an active market, with the fair value calculated on the basis of the last buy price quoted on the balance sheet date.

Contingent purchase consideration

Contingent purchase consideration refers to the estimated contingent additional purchase consideration for completed acquisitions.

In those cases where the amount is specified in the share purchase agreement, an estimate is made of how likely it is that the condition will be met. If it is considered likely, the purchase consideration is valued at 100% of the agreed amount. If it is considered unlikely, the purchase consideration is valued at 0% of the agreed amount.

In those cases where the amount is not specified in the share purchase agreement, but is calculated on the basis of performance, an estimate is made firstly of the amount and secondly of how likely it is that the condition will be met.

The fair value of contingent purchase considerations can be affected to an extent by currency risk. At the end of the reporting period, the fair value of contingent purchase considerations can be affected by changes in the SEK versus USD currency exchange rate. A change in the currency exchange rate for USD of 5 % would have an effect of SEK 5.0 million on the valuation of contingent purchase considerations and SEK 1.8 million on profit/loss before tax.

Note 9 Financial risks

ADDvise is exposed to a number of different financial risks through its activities, such as market risk, credit risk, currency risk and liquidity risk. The Group management and the Board of Directors take active steps to minimize these risks.

The Group's operations also involve a liquidity risk, since large orders tie up significant capital. To minimize the amount of capital tied up, the Group has payment terms with the Group's customers that require a portion of the order value to be paid in advance on the signing of the order. The Group also has factoring agreements in place.

Since the Group's strategy is to make complementary acquisitions, the Group's level of debt may change over time. The Board of Directors always makes an overall assessment of the risk that an acquisition loan represents to the Group.

Note 10 Number of shares

	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Weighted average number of shares before dilution	180,491,889	146,052,394	176,434,408	135,728,795	143,133,781	96,913,631
Adjustment on the calculation of basic earnings per share:						
Warrants	-	-	-	-	-	16,220,276
Weighted average number of shares after dilution	180,491,889	146,052,394	176,434,408	135,728,795	143,133,781	113,133,907

At the time of publication of this interim report, there were no warrants issued by the Group.

43,042,288 warrants in series 2019/2021 were issued outside the Group and listed for trading on Nasdaq First North. The subscription price for subscribing to class B shares on the basis of the warrant was SEK 0.65 per share. The exercise period ran from January 25, 2021, to February 8, 2021. Holders of warrants in series 2019/2021 exercised 42,787,137 warrants, corresponding to 99.41% of the number of outstanding warrants, for the subscription of 42,787,137 class B shares at the exercise price of SEK 0.65. The exercising of these warrants brought in SEK 27,811,639 for ADDvise before issue costs in February 2021.

Note 11 State subsidies and similar Covid-19-related items

During the Covid-19 pandemic, ADDvise has been applying for and receiving various kinds of state subsidies. Details are provided below of the state subsidies and similar Covid-19-related items that are recognized in the consolidated financial statements in this interim report.

State subsidies that are intended to compensate the company for costs relating to short-time working and similar personnel costs are recognized in profit and loss in the same period as the costs for which the subsidies are intended to compensate. The subsidies are recognized on the same rows as the costs in the consolidated statement of comprehensive income. During the Covid-19 pandemic, ADDvise has received subsidies for sick pay costs and subsidies for personnel costs in Sweden, as well as subsidies for personnel costs in the USA.

Reductions in charges are recognized in profit and loss in the periods to which the reduced charges relate. The reductions are recognized on the same rows as the charges. During 2020, ADDvise made use of the general reduction in employer's contribution offered by the Swedish Parliament as a result of Covid-19.

Some state subsidies relating to Covid-19 have been paid as advances and recognized in profit and loss when it is considered, with reasonable assurance, that the reporting of the utilization of the subsidy will be approved in accordance with the prevailing rules. The portion of the advance not yet utilized at the end of the reporting period, and therefore not yet recognized in profit and loss, is recognized in the consolidated statement of financial position on the row for Other current liabilities.

Items relating to state subsidies and similar Covid-19-related items that are recognized in profit and loss

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
State subsidies relating to short-time working and similar subsidies for personnel costs	128	325	3,714	2,035	2,997	5,203
State subsidies relating to sick pay costs	0	-4	77	43	43	106
Temporarily reduced employer's contributions	0	0	0	0	0	1,238
Total	128	321	3,791	2,079	3,040	6,547

continuation of Note 11; see next page

Items relating to state subsidies and similar Covid-19-related items that are recognized in the consolidated statement of financial position

SEK thousands	2022 Sep 30	2021 Sep 30	2021 Dec 31	2020 Dec 31
Other current liabilities relating to the payment of subsidies not yet recognized in profit and loss	0	948	0	306
Total	0	948	0	306

Liabilities relating to the payment of subsidies in advance result in a contingent liability to repay portions of the subsidy in the event that the reporting is not approved. At the end of the reporting period, this contingent liability amounted to SEK 0 thousand (5,075).

Note 12 Russia's invasion of Ukraine

As a result of the Russian invasion of Ukraine, we have stopped all business with companies in Russia and Belarus. We condemn Russia's actions and our thoughts go out to all those affected.

ADDvise has no subsidiaries or employees in Russia, Ukraine or Belarus and the direct business exposure is very limited. The indirect exposure and the total effect on net sales during the second quarter are also marginal overall.

Definition of key performance indicators

In its financial reports, ADDvise uses alternative performance measures, in other words financial measures that are not defined by IFRS. The company management uses these performance measures to assess the Group's financial development as a complement to the performance indicators that represent generally accepted accounting practice. Described below are financial measures not defined by IFRS. Unless otherwise stated in the respective key performance indicator definition, the Group's definition of the key performance indicator is unchanged from previous periods.

Financial measures that use items not otherwise presented in financial statements or by other facts in this interim report are described with detailed calculations.

Adjusted EBITDA

Operating profit/loss before depreciation and amortization, acquisition costs and non-recurring items.

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Operating profit/loss, see below	32,803	9,552	77,754	27,926	43,546	34,257
Plus reversal of depreciation and amortization	6,374	3,720	16,954	9,975	13,716	11,967
Plus reversal of acquisition costs	649	1,559	1,841	2,203	2,837	196
Plus reversal of restructuring costs	1,857	0	1,857	0	0	0
Minus reversal of state subsidies and similar items relating to Covid-19	-128	-321	-3,791	-2,079	-3,040	-6,547
Minus reversal of revaluation of estimated additional purchase consideration for completed acquisitions	-5,565	0	-5,565	0	0	-6,558
= Adjusted EBITDA	35,991	14,510	89,050	38,026	57,058	33,315

Adjusted EBITDA margin

Operating profit/loss before depreciation and amortization, acquisition costs and non-recurring items as a percentage of net revenue.

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Operating profit/loss, see below	32,803	9,552	77,754	27,926	43,546	34,257
Plus reversal of depreciation and amortization	6,374	3,720	16,954	9,975	13,716	11,967
Plus reversal of acquisition costs	649	1,559	1,841	2,203	2,837	196
Plus reversal of restructuring costs	1,857	0	1,857	0	0	0
Minus reversal of state subsidies and similar items relating to Covid-19	-128	-321	-3,791	-2,079	-3,040	-6,547
Minus reversal of revaluation of estimated additional purchase consideration for completed acquisitions	-5,565	0	-5,565	0	0	-6,558
= Adjusted EBITDA	35,991	14,510	89,050	38,026	57,058	33,315
Divided by net revenue	236,960	105,557	631,260	310,939	465,953	358,487
= Adjusted EBITDA margin as a %	15.2%	13.7%	14.1%	12.2%	12.2%	9.3%

Adjusted profit/loss for the period

Profit/loss for the period before acquisition costs and non-recurring items.

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Profit/loss for the period	33,901	-1,564	53,021	1,027	2,805	14,637
Plus reversal of acquisition costs	649	1,559	1,841	2,203	2,837	196
Plus reversal of restructuring costs	1,857	0	1,857	0	0	0
Plus reversal of financial expenses for liabilities relating to deferred payment of taxes and charges as a result of Covid-19	0	0	0	0	0	166
Plus reversal of financial expenses related to acquisitions and other non-recurring financial expenses	722	3,350	10,644	7,796	10,136	0
Minus reversal of state subsidies and similar items relating to Covid-19	-128	-321	-3,791	-2,079	-3,040	-6,547
Minus reversal of revaluation of estimated additional purchase consideration for completed acquisitions	-5,565	0	-5,565	0	0	-6,558
= Adjusted profit/loss for the period	31,437	3,025	58,008	8,947	12,739	1,894

Average number of shares after dilution

Weighted average of the number of shares outstanding during the period in the event that issued warrants are exercised. This performance indicator is as defined by IFRS, but is described here for information purposes.

Average number of shares before dilution

Weighted average of the number of shares outstanding during the period without taking into account issued warrants. This performance indicator is as defined by IFRS, but is described here for information purposes.

Basic earnings per share

Profit/loss for the period attributable to the parent company's shareholders as a proportion of the average number of shares before dilution, with earnings per share adjusted to take into account new share issues at a discount (the subscription price is lower than the current closing price). This performance indicator is as defined by IFRS, but is described here for information purposes.

Cash flow from Operations

As of the interim report for January–March 2022, cash flow from Operations is presented, which is cash flow from the Group's business operations, and where items attributable to acquisition activities having an impact on cash flow have been eliminated. The Group is presenting this key performance indicator as it has been requested by investors. Comparative figures have not been calculated, as 2020 and 2021 have been affected by the covid-19 pandemic to a greater extent than 2022. A comparison would therefore reflect the effects of the pandemic and not only developments in business operations.

SEK thousands	2022 Jul-Sep	2022 Jan-Sep
Operating profit/loss (EBIT)	32,803	77,754
Income taxes paid	2,532	4,077
Changes in working capital	-10,341	-35,241
Finance net attributable to Operations	180	451
Depreciation and amortization attributable to Operations	5,933	16,076
Acquisition of intangible and tangible non-current assets and payments made in relation to amortization of loans attributable to leases, attributable to Operations	-7,198	-18,296
Items attributable to acquisition activities	-3,059	-1,867
= Cash flow from Operations	20,850	42,954

Diluted earnings per share

Profit/loss for the year attributable to the parent company's shareholders as a proportion of the average number of shares after dilution, with earnings per share adjusted to take into account new share issues at a discount (the subscription price is lower than the current closing price). This performance indicator is as defined by IFRS, but is described here for information purposes.

EBITA

Operating profit/loss before amortization of intangible assets but after depreciation of property, plant and equipment. EBITA is a measure that the Group considers relevant for an investor wishing to understand profit generation before investments in intangible assets. The Group defines Earnings Before Interest, Tax and Amortization (EBITA) as operating profit/loss from continuing operations excluding amortization relating to intangible assets.

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Operating profit/loss, see below	32,803	9,552	77,754	27,926	43,546	34,257
Plus reversal of amortization of intangible assets	1,621	945	4,353	2,816	3,251	3,890
= EBITA	34,424	10,497	82,107	30,742	46,797	38,147

EBITA margin

Operating profit/loss before amortization of intangible assets but after depreciation of property, plant and equipment as a percentage of net revenue.

SEK thousands	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec	2020 Jan-Dec
Operating profit/loss, see below	32,803	9,552	77,754	27,926	43,546	34,257
Plus reversal of amortization of intangible assets	1,621	945	4,353	2,816	3,251	3,890
= EBITA	34,424	10,497	82,107	30,742	46,797	38,147
Divided by net revenue	236,960	105,557	631,260	310,939	465,953	358,487
= EBITA margin as a %	14.5%	9.9%	13.0%	9.9%	10.0%	10.6%

EBITDA

Operating profit/loss before depreciation and amortization. EBITDA is a measure that the Group considers relevant for an investor wishing to understand profit generation before investments in non-current assets. The Group defines Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) as operating profit/loss from continuing operations excluding depreciation and amortization relating to tangible and intangible assets.

EBITDA margin

Operating profit/loss before depreciation and amortization as a percentage of net revenue.

Equity per share

Equity at the end of the period attributable to the parent company's shareholders divided by the number of shares at the end of the period.

Equity ratio

Adjusted equity as a percentage of total assets.

Gross margin

Net revenue minus cost of materials as a percentage of net revenue. This performance indicator is presented in the interim report but not in the annual report. This is to facilitate comparison in quarterly follow-up.

Net debt

The Group defines net debt as the net sum of cash and cash equivalents, plus short-term investments and interest-bearing liabilities. The Group monitors this performance indicator since it shows the level of debt and is part of one of the long-term financial targets adopted by the Board of Directors.

Net debt-to-EBITDA

The Group defines net debt-to-EBITDA as the net sum of cash and cash equivalents plus short-term investments and interest-bearing liabilities divided by EBITDA on a rolling 12-month basis. The Group monitors this performance indicator since it shows the level of debt and is one of the financial targets adopted by the Board of Directors. For the definition of EBITDA, see above.

Net debt-to-EBITDA according to bond term sheet

The Group defines net debt according to the bond term sheet as the net sum of cash and cash equivalents, plus short-term investments and liabilities to be included in net debt according to the bond term sheet. The calculation of net debt-to-EBITDA according to the bond term sheet is different from the Group's net debt/EBITDA key performance indicator, which is one of the Group's financial targets. The Group follows the net debt-to-EBITDA according to the bond term sheet key performance indicator as it constitutes the terms of the Group's bond to do so. The key performance indicator is not calculated retroactively, so comparative figures are not presented for periods before the bond loan was issued, in May 2021. In the interim report for January–September, the presentation of the calculation of net debt has been changed.

SEK thousands	2022 Sep 30	2021 Sep 30	2021 Dec 31
Cash and cash equivalents	123,977	139,845	325,735
Excluding cash from bond loan deposited in escrow account	0	0	-168,274
Excluding purchase price paid in cash for acquisitions after the end of the reporting period net with acquired cash and cash equivalents	0	0	-65,917
Loans due for repayment within one year	-29,181	-48,909	-29,044
Loans due for repayment after one year or more	-530,481	-272,504	-525,145
Excluding bond loan related to cash from bond loan deposited in escrow account	0	0	168,274
Acquisition-related liabilities	-67,928	-19,068	-20,257
Acquisition-related liabilities for acquisitions after the end of the reporting period	0	0	-37,159
= Net debt according to bond term sheet	-503,612	-200,636	-351,787
EBITDA rolling 12-month period	114,068	54,176	57,261
Plus reversal of acquisition costs rolling 12-month period minus reversal of revaluation of estimated earn-outs for completed acquisitions rolling 12-month period and adjusted for other non-recurring items	-1,233	-1,365	2,837
Plus pro forma EBITDA from new acquisitions	40,509	24,711	22,929
Plus pro forma EBITDA from new acquisitions after the end of the reporting period	0	0	17,126
= EBITDA rolling 12-month period according to bond term sheet	153,343	77,522	100,154
= Net debt-to-EBITDA according to bond term sheet	3.3	2.6	3.5

Net margin

Profit/loss after net financial items (profit/loss before tax, EBT) as a percentage of net revenue.

Number of employees

The number of employees working at the end of the period.

Operating margin

Operating profit/loss as a percentage of net revenue.

Operating profit/loss (EBIT)

Profit/loss before financial items and tax.

OPEX

The Group defines OPEX (operating expenses) as the sum of other external expenses, personnel costs and other operating expenses. The Group monitors this performance indicator since it shows the effectiveness of cost-saving initiatives and cost control.

Orders received

New customer orders received during the period, plus additions and deductions for changes to customer orders received earlier in the current financial year. Additions and deductions are made for changes to larger customer orders with delivery schedules spread across several financial years even if the customer order was received in a previous year.

Orders received for 2021 have been recalculated as a result of the one-off order of SEK 50.0 million received in the first quarter of 2020 for the years 2020–2022, instead of being seen as an order received in 2020, now being allocated over 3 years.

Profit/loss before tax (EBT)

Profit/loss after net financial items.

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group's operations are divided into two business units, Lab and Healthcare, with a highly decentralized organization. Each company operates as a distinctly separate unit and is run independently in order to maintain its own inventiveness and entrepreneurial flair. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise.

Our acquisition strategy

Acquisition is one of the most important components of the ADDvise Group's growth strategy. The purpose of the acquisitions is to create critical mass in the different industries in which the Group does business. The industrial logic in the acquisitions will create long-term value for the company's shareholders. Focus is directed at companies within the life science sector, which constitutes the core of the ADDvise Group.

Share and bond

The company's class A share is listed at the S SME trading venue, on the Nasdaq First North Premier Growth Market Sweden. The stock short name is ADDV A and the share's


ISIN code is SE0001306119. One (1) class A share equals one (1) vote.

The company's class B share is listed at the S SME trading venue, on the Nasdaq First North Premier Growth Market Sweden. The stock short name is ADDV B and the share's ISIN code is SE0007464862. One (1) class B share equals one-tenth (1/10) of a vote.

The company's bonds are registered for trading on the Corporate Bond List on Nasdaq Stockholm. The bonds' short name is ADDV02 with ISIN code SE0015222088.

Legal structure

The parent company ADDvise Group AB (publ), company registration number 556363-2115, was registered on July 6, 1989, and has its registered office in Stockholm. At the end of the reporting period, ADDvise had 28 subsidiaries. Operations are conducted at the parent company and all subsidiaries.



Other information

Publication dates for financial information

Year-end report 2022	February 23, 2023
Annual report and sustainability report 2022	April 5, 2023
Interim report Jan-Mar 2023	April 20, 2023
Interim report Jan-Jun 2023	July 20, 2023
Interim report Jan-Sep 2023	November 2, 2023
Year-end report 2023	February 29, 2024

This information is information that ADDvise is obliged to publish under the Swedish Securities Market Act. The information was submitted for publication on October 28, 2022 at 08.15 CEST.

This report, as well as further information, is available on ADDvise's website, www.addvisigroup.com

For further information, please contact:

Rikard Akhtarzand, CEO
+46(0)8 128 766 08
rikard.akhtarzand@addvisigroup.se

Sebastian Robson, CFO
+46 (0)70-441 84 48
sebastian.robson@addvisigroup.se

ADDvise Group AB (publ)
Grev Turegatan 30, SE-114 38 Stockholm
Sweden

Certified Adviser

Mangold Fondkommission AB, +46(0)8 503 015 50, is the company's Certified Adviser and liquidity guarantor.

Review of interim report

The Swedish version of this interim report has been reviewed by the company's auditor.

Declaration

The undersigned declare that the interim report presents fairly the business, financial position and performance of the parent company and the Group and describes the significant risks and uncertainties faced by the parent company and the constituent companies of the Group.

Stockholm, October 28, 2022

Staffan Torstensson

Chairman of the Board

Johanne Louise Brændgaard

Board Member

Fredrik Celsing

Board Member

Anna Ljung

Board Member

Erland Pontusson

Board Member